{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T12:28:24Z","timestamp":1793104104626,"version":"4.5.0"},"reference-count":75,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,9,12]],"date-time":"2024-09-12T00:00:00Z","timestamp":1726099200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Sulfasalazine is a widely used anti-inflammatory medication for treating autoimmune disorders such as ulcerative colitis (UC), Crohn\u2019s disease, and rheumatoid arthritis. However, its safety profile has not been systematically evaluated in real-world settings. By analyzing the FDA Adverse Event Reporting System (FAERS) database, we identified risk signals associated with adverse reactions to sulfasalazine, offering valuable insights for clinical decision-making and risk management.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Reports of adverse events (AEs) associated with sulfasalazine, covering the period from Q1 2004 to Q4 2023, were extracted from the FAERS database. Detailed case information was aggregated to assess demographic characteristics. The associations between sulfasalazine and adverse events were evaluated using the Proportional Reporting Ratio (PRR), Reporting Odds Ratio (ROR), Bayesian Confidence Propagation Neural Network (BCPNN), and Empirical Bayes Geometric Mean (EBGM).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>We extracted 7,156 adverse event reports from the FAERS database where sulfasalazine was identified as the \u201cPrimary Suspect (PS)\u201d drug. Using disproportionality analysis, we identified 101 preferred terms (PT) related to sulfasalazine across 24 organ systems. Notable adverse reactions consistent with the drug\u2019s labeling were observed, including Stevens-Johnson syndrome, agranulocytosis, eosinophilic pneumonia, and crystalluria. Additionally, novel positive signals not previously documented in the drug label were identified, including acute febrile neutrophilic dermatosis, aseptic meningitis, glomerulonephritis, and hepatosplenic T-cell lymphoma.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Most of the adverse reaction findings in this study are consistent with previous clinical research, and we have also identified new potential AEs associated with sulfasalazine. These findings provide valuable insights for the safety monitoring and clinical application of sulfasalazine.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fphar.2024.1452300","type":"journal-article","created":{"date-parts":[[2024,9,12]],"date-time":"2024-09-12T01:27:34Z","timestamp":1726104454000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":23,"title":["Safety assessment of sulfasalazine: a pharmacovigilance study based on FAERS database"],"prefix":"10.3389","volume":"15","author":[{"given":"Wangyu","family":"Ye","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meng","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhihua","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaoli","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,9,12]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"611","DOI":"10.4103\/0378-6323.45103","article-title":"An uncontrolled, open label study of sulfasalazine in severe alopecia areata","volume":"74","author":"Aghaei","year":"2008","journal-title":"Indian J. Dermatol Venereol. Leprol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"2042098620938595","DOI":"10.1177\/2042098620938595","article-title":"Post marketing surveillance of suspected adverse drug reactions through spontaneous reporting: current status, challenges and the future","volume":"11","author":"Alomar","year":"2020","journal-title":"Ther. Adv. Drug Saf."},{"key":"B3","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1097\/MOH.0b013e3282f15fb9","article-title":"Idiosyncratic drug-induced agranulocytosis or acute neutropenia","volume":"15","author":"Andr\u00e8s","year":"2008","journal-title":"Curr. Opin. Hematol."},{"key":"B4","first-page":"45","article-title":"Composite lymphoma in a patient with ulcerative colitis: a case report","volume":"8","author":"Ashrafi","year":"2014","journal-title":"Int. J. Hematol. Oncol. Stem Cell Res."},{"key":"B5","doi-asserted-by":"publisher","first-page":"369","DOI":"10.2515\/therapie\/2013064","article-title":"Adverse effects of sulfasalazine: discussion of mechanism and role of sulfonamide structure","volume":"68","author":"Atheymen","year":"2013","journal-title":"Therapie"},{"key":"B6","first-page":"343","article-title":"Sulfasalazine pneumonitis","volume":"80","author":"Averbuch","year":"1985","journal-title":"Am. J. Gastroenterol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"e14","DOI":"10.1056\/NEJMicm2033219","article-title":"Acute febrile neutrophilic dermatosis","volume":"385","author":"Ayyash","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"B8","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1111\/j.1365-2125.1982.tb01415.x","article-title":"The disposition and metabolism of sulphasalazine (salicylazosulphapyridine) in man","volume":"13","author":"Azadkhan","year":"1982","journal-title":"Br. J. Clin. Pharmacol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.bpobgyn.2019.09.004","article-title":"Paternal safety of anti-rheumatic medications","volume":"64","author":"Bermas","year":"2020","journal-title":"Best. Pract. Res. Clin. Obstet. Gynaecol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"CD004800","DOI":"10.1002\/14651858.CD004800.pub3","article-title":"Sulfasalazine for ankylosing spondylitis","volume":"2014","author":"Chen","year":"2014","journal-title":"Cochrane Database Syst. Rev."},{"key":"B11","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1080\/1744666X.2019.1705785","article-title":"Infection risk in patients undergoing treatment for inflammatory arthritis: non-biologics versus biologics","volume":"16","author":"Chiu","year":"2020","journal-title":"Expert Rev. Clin. Immunol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"406","DOI":"10.2165\/00003088-197601060-00002","article-title":"Clinical pharmacokinetics of sulphasalazine","volume":"1","author":"Das","year":"1976","journal-title":"Clin. Pharmacokinet."},{"key":"B13","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1016\/j.jaci.2017.02.013","article-title":"Biologic response modifiers: indications, implications, and insights","volume":"139","author":"Davis","year":"2017","journal-title":"J. Allergy Clin. Immunol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1177\/106002808802200208","article-title":"Agranulocytosis associated with sulfasalazine","volume":"22","author":"Dery","year":"1988","journal-title":"Drug Intell. Clin. Pharm."},{"key":"B15","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1053\/j.ajkd.2017.05.013","article-title":"Sulfasalazine-induced crystalluria causing severe acute kidney injury","volume":"70","author":"Durando","year":"2017","journal-title":"Am. J. Kidney Dis."},{"key":"B16","first-page":"504","article-title":"Editorial: sulphasalazine-induced lung disease","volume":"2","year":"1974","journal-title":"Lancet."},{"key":"B17","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1093\/rheumatology\/30.6.413","article-title":"Immunodeficiencies associated with sulphasalazine therapy in inflammatory arthritis","volume":"30","author":"Farr","year":"1991","journal-title":"Br. J. Rheumatol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1007\/s11096-015-0107-2","article-title":"Sulfasalazine-induced DRESS and severe agranulocytosis successfully treated by granulocyte colony-stimulating factor","volume":"37","author":"Fathallah","year":"2015","journal-title":"Int. J. Clin. Pharm."},{"key":"B19","first-page":"401","article-title":"Sulfasalazine hepatotoxicity","volume":"79","author":"Fich","year":"1984","journal-title":"Am. J. Gastroenterol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1038\/nri2394","article-title":"The X-files in immunity: sex-based differences predispose immune responses","volume":"8","author":"Fish","year":"2008","journal-title":"Nat. Rev. Immunol."},{"key":"B21","first-page":"1654","article-title":"Pulmonary infiltrates and skin pigmentation associated with sulfasalazine","volume":"87","author":"Gabazza","year":"1992","journal-title":"Am. J. Gastroenterol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"409152","DOI":"10.1155\/2013\/409152","article-title":"A new case of DRESS syndrome induced by sulfasalazine and triggered by amoxicillin","volume":"2013","author":"Girelli","year":"2013","journal-title":"Case Rep. Rheumatol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"265","DOI":"10.3109\/03009748509100404","article-title":"Does sulphasalazine cause folate deficiency in rheumatoid arthritis?","volume":"14","author":"Grindulis","year":"1985","journal-title":"Scand. J. Rheumatol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1378\/chest.101.4.1033","article-title":"Sulfasalazine-induced pulmonary disease","volume":"101","author":"Hamadeh","year":"1992","journal-title":"Chest"},{"key":"B25","doi-asserted-by":"publisher","first-page":"3","DOI":"10.15171\/bi.2016.01","article-title":"Sulfasalazine-induced renal and hepatic injury in rats and the protective role of taurine","volume":"6","author":"Heidari","year":"","journal-title":"Bioimpacts"},{"key":"B26","doi-asserted-by":"publisher","first-page":"137","DOI":"10.3109\/0886022X.2015.1096731","article-title":"Sulfasalazine-induced renal injury in rats and the protective role of thiol-reductants","volume":"38","author":"Heidari","year":"","journal-title":"Ren. Fail"},{"key":"B27","doi-asserted-by":"publisher","first-page":"18","DOI":"10.2165\/00003495-198600321-00005","article-title":"Pharmacological and biochemical actions of sulphasalazine","volume":"32","author":"Hoult","year":"1986","journal-title":"Drugs"},{"key":"B28","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1097\/01.mib.0000231569.43065.a4","article-title":"Erythroderma and toxic epidermal necrolysis caused by to 5-aminosalacylic acid","volume":"12","author":"Iemoli","year":"2006","journal-title":"Inflamm. Bowel Dis."},{"key":"B29","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1002\/j.1875-9114.1995.tb04352.x","article-title":"The risk of sulfasalazine- and mesalazine-associated blood disorders","volume":"15","author":"Jick","year":"1995","journal-title":"Pharmacotherapy"},{"key":"B30","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1080\/10715760500177880","article-title":"Free radical scavenging reactions of sulfasalazine, 5-aminosalicylic acid and sulfapyridine: mechanistic aspects and antioxidant activity","volume":"39","author":"Joshi","year":"2005","journal-title":"Free Radic. Res."},{"key":"B31","first-page":"7","article-title":"Production of congenital anomalies in fetuses of rats and mice with various sulfonamides","volume":"13","author":"Kato","year":"1973","journal-title":"Cong Anom."},{"key":"B32","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1111\/j.1346-8138.2005.tb00885.x","article-title":"Drug-induced hypersensitivity syndrome associated with human herpesvirus 6 and cytomegalovirus reactivation","volume":"32","author":"Komura","year":"2005","journal-title":"J. Dermatol"},{"key":"B33","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.cgh.2010.09.016","article-title":"A systematic review of factors that contribute to hepatosplenic T-cell lymphoma in patients with inflammatory bowel disease","volume":"9","author":"Kotlyar","year":"2011","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1038\/ajg.2018.27","article-title":"ACG clinical guideline: management of Crohn's disease in adults","volume":"113","author":"Lichtenstein","year":"2018","journal-title":"Am. J. Gastroenterol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"CD008870","DOI":"10.1002\/14651858.CD008870.pub2","article-title":"Aminosalicylates for induction of remission or response in Crohn's disease","volume":"7","author":"Lim","year":"2016","journal-title":"Cochrane Database Syst. Rev."},{"key":"B36","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.tox.2008.11.010","article-title":"Lipid peroxidation and antioxidant status in kidney and liver of rats treated with sulfasalazine","volume":"256","author":"Linares","year":"2009","journal-title":"Toxicology"},{"key":"B37","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1517\/14740338.2011.529898","article-title":"Oxidative stress as a mechanism underlying sulfasalazine-induced toxicity","volume":"10","author":"Linares","year":"2011","journal-title":"Expert Opin. Drug Saf."},{"key":"B38","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1007\/s00228-022-03358-3","article-title":"Evolution of adverse drug reactions reporting systems: paper based to software based","volume":"78","author":"Madhushika","year":"2022","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"B39","doi-asserted-by":"publisher","first-page":"23","DOI":"10.4103\/idoj.idoj_530_21","article-title":"The clinical characteristics, putative drugs, and optimal management of 62 patients with stevens-johnson syndrome and\/or toxic epidermal necrolysis: a retrospective observational study","volume":"13","author":"Manvi","year":"2022","journal-title":"Indian Dermatol Online J."},{"key":"B40","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1016\/j.jaad.2009.03.027","article-title":"Guidelines of care for the management of psoriasis and psoriatic arthritis: section 4. Guidelines of care for the management and treatment of psoriasis with traditional systemic agents","volume":"61","author":"Menter","year":"2009","journal-title":"J. Am. Acad. Dermatol"},{"key":"B41","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1007\/BF01309523","article-title":"Sulfasalazine-induced pulmonary disease","volume":"30","author":"Moseley","year":"1985","journal-title":"Dig. Dis. Sci."},{"key":"B42","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/s0954-6111(06)80215-5","article-title":"Time course of recovery of lung function in sulphasalazine-induced alveolitis","volume":"85","author":"Moss","year":"1991","journal-title":"Respir. Med."},{"key":"B43","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1097\/00004836-198106000-00017","article-title":"Reversible sulfasalazine-induced granulomatous hepatitis","volume":"3","author":"Namias","year":"1981","journal-title":"J. Clin. Gastroenterol."},{"key":"B44","doi-asserted-by":"publisher","first-page":"101496","DOI":"10.1016\/j.rmcr.2021.101496","article-title":"Sulfa-induced acute eosinophilic pneumonia","volume":"34","author":"Nasim","year":"2021","journal-title":"Respir. Med. Case Rep."},{"key":"B45","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1007\/s42770-023-00978-4","article-title":"Cladosporium tenuissimum-induced sinusitis in a woman with immune-deficiency disorder","volume":"54","author":"Nasiri-Jahrodi","year":"2023","journal-title":"Braz J. Microbiol."},{"key":"B46","doi-asserted-by":"publisher","first-page":"S18","DOI":"10.1016\/j.amjgastroenterol.2003.11.001","article-title":"Treatment of inflammatory bowel disease: safety and tolerability issues","volume":"98","author":"Navarro","year":"2003","journal-title":"Am. J. Gastroenterol."},{"key":"B47","doi-asserted-by":"publisher","first-page":"528","DOI":"10.5694\/j.1326-5377.1983.tb136199.x","article-title":"Possible teratogenicity of sulphasalazine","volume":"1","author":"Newman","year":"1983","journal-title":"Med. J. Aust."},{"key":"B48","doi-asserted-by":"publisher","first-page":"e0243010","DOI":"10.1371\/journal.pone.0243010","article-title":"NF-kappa-B activation unveils the presence of inflammatory hotspots in human gut xenografts","volume":"16","author":"Nissim-Eliraz","year":"2021","journal-title":"PLoS One"},{"key":"B49","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1046\/j.1365-2036.2001.00962.x","article-title":"Population-based case control study of the safety of sulfasalazine use during pregnancy","volume":"15","author":"N\u00f8rg\u00e5rd","year":"2001","journal-title":"Aliment. Pharmacol. Ther."},{"key":"B50","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1183\/09031936.02.00267402","article-title":"Sulphasalazine and lung toxicity","volume":"19","author":"Parry","year":"2002","journal-title":"Eur. Respir. J."},{"key":"B51","doi-asserted-by":"publisher","first-page":"1220","DOI":"10.2215\/CJN.11290821","article-title":"Drug-induced acute kidney injury","volume":"17","author":"Perazella","year":"2022","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"B52","doi-asserted-by":"publisher","first-page":"1825","DOI":"10.2165\/00003495-200565130-00008","article-title":"Sulfasalazine: a review of its use in the management of rheumatoid arthritis","volume":"65","author":"Plosker","year":"2005","journal-title":"Drugs"},{"key":"B53","doi-asserted-by":"publisher","first-page":"1901","DOI":"10.1016\/s0006-2952(97)00137-8","article-title":"Inhibition of extracellular release of proinflammatory secretory phospholipase A2 (sPLA2) by sulfasalazine: a novel mechanism of anti-inflammatory activity","volume":"53","author":"Pruzanski","year":"1997","journal-title":"Biochem. Pharmacol."},{"key":"B54","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.reprotox.2007.11.010","article-title":"Pregnancy outcome in women with inflammatory bowel disease following exposure to 5-aminosalicylic acid drugs: a meta-analysis","volume":"25","author":"Rahimi","year":"2008","journal-title":"Reprod. Toxicol."},{"key":"B55","doi-asserted-by":"publisher","first-page":"137","DOI":"10.2165\/00003495-199550010-00009","article-title":"Sulfasalazine. A review of its pharmacological properties and therapeutic efficacy in the treatment of rheumatoid arthritis","volume":"50","author":"Rains","year":"1995","journal-title":"Drugs"},{"key":"B56","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1136\/gut.51.4.536","article-title":"Sulphasalazine and mesalazine: serious adverse reactions re-evaluated on the basis of suspected adverse reaction reports to the Committee on Safety of Medicines","volume":"51","author":"Ransford","year":"2002","journal-title":"Gut"},{"key":"B57","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/j.therap.2015.11.006","article-title":"Sulfasalazine-induced Sweet's syndrome","volume":"71","author":"Romdhane","year":"2016","journal-title":"Therapie"},{"key":"B58","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1080\/03009742.2020.1747533","article-title":"Sulfasalazine-induced mononucleosis-like-illness and haemolysis","volume":"50","author":"Sahm","year":"2021","journal-title":"Scand. J. Rheumatol."},{"key":"B59","doi-asserted-by":"publisher","first-page":"423","DOI":"10.2515\/therapie\/2013065","article-title":"Sulfasalazine-induced aseptic meningitis with positive rechallenge: a case report and review of the literature","volume":"68","author":"Salouage","year":"2013","journal-title":"Therapie"},{"key":"B60","doi-asserted-by":"publisher","first-page":"CD000958","DOI":"10.1002\/14651858.CD000958","article-title":"Sulfasalazine for rheumatoid arthritis","volume":"1998","author":"Suarez-Almazor","year":"2000","journal-title":"Cochrane Database Syst. Rev."},{"key":"B61","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/s12893-021-01060-2","article-title":"Diffuse large B-cell lymphoma originating from the rectum and diagnosed after rectal perforation during the treatment of ulcerative colitis: a case report","volume":"21","author":"Suzuki","year":"2021","journal-title":"BMC Surg."},{"key":"B62","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1007\/BF01296907","article-title":"Sulfasalazine. Adverse effects and desensitization","volume":"28","author":"Taffet","year":"1983","journal-title":"Dig. Dis. Sci."},{"key":"B63","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1097\/ACI.0000000000000288","article-title":"Relapsing drug-induced hypersensitivity syndrome","volume":"16","author":"Tan","year":"2016","journal-title":"Curr. Opin. Allergy Clin. Immunol."},{"key":"B64","doi-asserted-by":"publisher","first-page":"e71","DOI":"10.1111\/j.1756-185X.2012.01705.x","article-title":"Sulphasalazine-induced aseptic meningitis with facial and nuchal edema in a patient with spondyloarthritis","volume":"15","author":"Tay","year":"2012","journal-title":"Int. J. Rheum. Dis."},{"key":"B65","first-page":"237","article-title":"Sulphasalazine-induced DRESS","volume":"47","author":"Teo","year":"2006","journal-title":"Singap. Med. J."},{"key":"B66","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1016\/j.crohns.2010.05.006","article-title":"Hepatosplenic T-cell lymphoma and inflammatory bowel disease","volume":"4","author":"Thai","year":"2010","journal-title":"J. Crohns Colitis"},{"key":"B67","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1517\/13543784.10.1.21","article-title":"Therapeutic advances in ankylosing spondylitis","volume":"10","author":"Toussirot","year":"2001","journal-title":"Expert Opin. Investig. Drugs"},{"key":"B68","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1016\/j.crohns.2011.03.014","article-title":"Stevens-Johnson syndrome with sulfasalazine treatment: report of two cases","volume":"5","author":"Tremblay","year":"2011","journal-title":"J. Crohns Colitis"},{"key":"B69","doi-asserted-by":"publisher","first-page":"196","DOI":"10.3109\/03009742.2011.626442","article-title":"Outcomes after anti-rheumatic drug use before and during pregnancy: a cohort study among 150,000 pregnant women and expectant fathers","volume":"41","author":"Viktil","year":"2012","journal-title":"Scand. J. Rheumatol."},{"key":"B70","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1002\/cpt.805","article-title":"Sulfasalazine-induced agranulocytosis is associated with the human leukocyte antigen locus","volume":"103","author":"Wadelius","year":"2018","journal-title":"Clin. Pharmacol. Ther."},{"key":"B71","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1038\/ni0901-777","article-title":"Sex differences in autoimmune disease","volume":"2","author":"Whitacre","year":"2001","journal-title":"Nat. Immunol."},{"key":"B72","doi-asserted-by":"publisher","first-page":"e263","DOI":"10.1111\/ijd.12260","article-title":"Simultaneous occurrence of Sweet's syndrome and erythema nodosum possibly associated with sulfasalazine","volume":"53","author":"Yamamoto","year":"2014","journal-title":"Int. J. Dermatol"},{"key":"B73","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1111\/fcp.12349","article-title":"Drug-induced aseptic meningitis: a mini-review","volume":"32","author":"Yelehe-Okouma","year":"2018","journal-title":"Fundam. Clin. Pharmacol."},{"key":"B74","doi-asserted-by":"publisher","first-page":"713","DOI":"10.2165\/11536520-000000000-00000","article-title":"Medications and glucose-6-phosphate dehydrogenase deficiency: an evidence-based review","volume":"33","author":"Youngster","year":"2010","journal-title":"Drug Saf."},{"key":"B75","doi-asserted-by":"publisher","first-page":"3146","DOI":"10.3748\/wjg.v20.i12.3146","article-title":"Immunosuppressive therapies for inflammatory bowel disease","volume":"20","author":"Zenlea","year":"2014","journal-title":"World J. Gastroenterol."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2024.1452300\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,12]],"date-time":"2024-09-12T01:27:43Z","timestamp":1726104463000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2024.1452300\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,12]]},"references-count":75,"alternative-id":["10.3389\/fphar.2024.1452300"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2024.1452300","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,12]]},"article-number":"1452300"}}